Entrada Therapeutics Inc(TRDA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:59 PM ET (Korea 10/31 05:59)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.97 | Insider Own | 38.6% | Shs Outstand | 38.9M | Perf Week | 2.83% |
| Market Cap | 0.18B | Forward P/E | - | EPS next Y | 13.2% | Insider Trans | -8.96% | Shs Float | 23.9M | Perf Month | -20.16% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -1.01 | Inst Own | 53.48% | Short Float | 13.68% | Perf Quarter | -37.53% |
| Income | -0.17B | P/S | 37.65 | EPS this Y | -11.89% | Inst Trans | 1.57% | Short Ratio | 9.39 | Perf Half Y | -68.72% |
| Sales | 0.00B | P/B | 0.76 | EPS next 5Y | 4.82% | ROA | -44.35% | Short Interest | 3.27M | Perf YTD | -55.89% |
| Book/sh | 5.99 | P/C | 0.79 | EPS past 3/5Y | -4.74% -32.56% | ROE | -54.09% | 52W High | -72.43% ($16.45) | Perf Year | -34.28% |
| Cash/sh | 5.73 | P/FCF | - | Sales past 3/5Y | - | ROIC | -59.74% | 52W Low | 10.36% ($4.11) | Perf 3Y | -70.49% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -122.58% | Gross Margin | 21.23% | Volatility(W/M) | 11.74% 10.46% | Perf 5Y | -81.06% |
| Dividend TTM | - | EV/Sales | 0.45 | Sales Y/Y TTM | -94.1% | Oper. Margin | -3767.07% | ATR (14) | 0.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.89 | EPS Q/Q | 2.87% | Profit Margin | -3537.73% | RSI (14) | 40.8 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.89 | Sales Q/Q | -53.95% | SMA20 | -7.74% ($4.91) | Beta | -0.24 | Target Price | $17 |
| Payout | - | Debt/Eq | 0.21 | Earnings | 2026/8/5 | SMA50 | -24.98% ($6.04) | Rel Volume | 0.91 | Prev Close | $4.4 |
| Employees | 152 | LT Debt/Eq | 0.19 | EPS/Sales Surpr. | 3.75% -59.81% | SMA200 | -48.29% ($8.76) | Avg Volume(3M) | 0.35M | Price | $4.53 |
| IPO | 2021/10/29 | Option/Short | Yes/Yes | Trades | 2639 | Volume | 316,088 | Change | 3.07% |
A U.S. clinical-stage biotech company developing RNA therapeutics based on its proprietary endosomal escape delivery platform. It targets rare neuromuscular diseases, including Duchenne muscular dystrophy, as well as ophthalmologic conditions, with its intracellular drug delivery technology serving as its core competitive advantage.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded about as much as usual. That is 91% of its average volume.
TRDA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -11.9% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,765. Peers typically go for $1,010. It is about in line with its own 1-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -81.1%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 53.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #310 of 595 in the industry
Based on market cap of $177M.
TRDA#310 Entrada Therapeutics Inc $177M PER - 
SION#311 Sionna Therapeutics Inc $175M PER - 
MDWD#312 MediWound Ltd $172M PER - 
IVVD#313 Invivyd Inc $171M PER - 
ORMP#314 Oramed Pharmaceuticals Inc $171M PER 1.0 
FAQ
What kind of company is TRDA?
TRDA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TRDA?
The market cap of TRDA is approximately $177M, ranking 4,102 within its sector.
What is the 52-week high and low for TRDA?
TRDA has recorded a 52-week high of $16.45 and a low of $4.11.
